+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dopamine Agonist Market Size, Share & Trends Analysis Report by Drug (Non-Ergot Dopamine Agonists, Ergot Alkaloids), Route of Administration (Oral, Injectable), Application, Distribution Channel, and Region with Growth Forecasts, 2025-2030- Product Image
Dopamine Agonist Market Size, Share & Trends Analysis Report by Drug (Non-Ergot Dopamine Agonists, Ergot Alkaloids), Route of Administration (Oral, Injectable), Application, Distribution Channel, and Region with Growth Forecasts, 2025-2030- Product Image
New

Dopamine Agonist Market Size, Share & Trends Analysis Report by Drug (Non-Ergot Dopamine Agonists, Ergot Alkaloids), Route of Administration (Oral, Injectable), Application, Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 153 Pages
  • February 2025
  • Region: Global
  • Grand View Research
  • ID: 6056059
Description Jump to:
The Dopamine Agonist Market was valued at USD 1.31 billion in 2024, and is projected to reach USD 1.83 billion by 2030, rising at a CAGR of 5.70%. The demand for dopamine agonists in neurological treatments, including ergot alkaloids and non-ergot dopamine agonists, is creating significant opportunities in the pharmaceutical sector. These drugs, which have demonstrated effectiveness in managing conditions like Parkinson’s disease, restless legs syndrome (RLS), and hyperprolactinemia, are driving market expansion. Ergot-derived dopamine agonists have long been used in clinical practice, while non-ergot dopamine agonists are gaining preference due to their improved safety profiles and tolerability. With growing clinical evidence supporting their efficacy, the acceptance of dopamine agonists in managing movement disorders continues to rise.

The development of oral and injectable formulations further broadens treatment accessibility and patient preference. Oral dopamine agonists are widely used for chronic conditions like Parkinson’s disease and RLS, allowing for convenient administration and long-term adherence. Injectable formulations, on the other hand, play a crucial role in managing acute or advanced-stage cases where immediate and sustained drug action is required. With pharmaceutical companies focusing on developing innovative drug delivery methods, the market is poised for further growth.

Pharmaceutical companies such as Teva Pharmaceutical Industries Ltd., GSK plc., Supernus Pharmaceuticals, Inc., H. Lundbeck A/S, Amneal Pharmaceuticals LLC, UCB Pharma, Novartis AG, VeroScience LLC., Pfizer Inc., and Boehringer Ingelheim Pharmaceuticals, Inc. are actively contributing to the expansion of the market. These companies are engaged in research and development efforts to improve drug efficacy, safety, and patient compliance, further driving the adoption of these therapies.

Retail pharmacies play an increasing role in the distribution of dopamine agonists, particularly for oral formulations used in chronic disease management. These pharmacies offer not only easy access to medications but also patient education and counseling services to ensure adherence and optimal treatment outcomes. The ability of retail pharmacies to provide consistent medication refills and support makes them a key component in long-term patient care.

Hospital pharmacies remain crucial, especially in the initial stages of treatment, when close monitoring is essential. Parkinson’s disease patients, for instance, often begin therapy under hospital supervision before transitioning to outpatient care. As patients stabilize, retail and specialty pharmacies become primary sources for continued medication access and support services, ensuring uninterrupted treatment for chronic neurological disorders.

As the demand for dopamine agonists continues to rise, challenges such as supply chain management and drug distribution will emerge. Ensuring the consistent availability of both oral and injectable therapies will require a strong logistics infrastructure and a focus on patient education to maximize adherence and therapeutic outcomes. Moreover, continued investment in research and development, particularly for novel delivery systems, presents an opportunity for pharmaceutical companies to cater to a broader patient population and enhance treatment effectiveness.

Dopamine Agonist Market Report Highlights

  • In 2024, non-ergot dopamine agonists dominated the market, solidifying their position as the preferred treatment option for neurological disorders. Their superior safety profile, improved tolerability, and growing clinical acceptance make them the leading therapy in this class.
  • The oral segment dominated the market in 2024. Oral formulations are widely preferred due to their convenience, long-term adherence benefits, and effectiveness in managing chronic conditions like Parkinson’s disease, restless legs syndrome (RLS), and hyperprolactinemia.
  • Retail pharmacies emerged as the dominant distribution channel in 2024. The growing convenience and accessibility offered by retail pharmacies made them the primary point of access for patients using dopamine agonist medications.
  • North America led the market, attributed to factors such as a well-established healthcare infrastructure, high awareness of neurological disorders, and the availability of advanced treatment options.

This report addresses:

  • Market intelligence to enable effective decision-making.
  • Market estimates and forecasts from 2018 to 2030.
  • Growth opportunities and trend analyses.
  • Segment and regional revenue forecasts for market assessment.
  • Competition strategy and market share analysis.
  • Product innovation listings for you to stay ahead of the curve.
  • COVID-19's impact and how to sustain in this fast-evolving market.

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Dopamine Agonist Market Variables, Trends, & Scope
3.1. Parent Market Outlook
3.2. Ancillary Market Outlook
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.1.1. Rising prevalence of neurological disorders
3.3.1.2. Growing geriatric population
3.3.1.3. Advancements in drug formulations & delivery methods
3.3.2. Market Restraints Analysis
3.3.2.1. Severe side effects & safety concerns
3.3.2.2. Emerging alternative therapies
3.4. Dopamine Agonist Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
3.5. Pipeline Analysis
3.5.1. Phase 1
3.5.2. Phase 2
3.5.3. Phase 3
Chapter 4. Dopamine Agonist Market: By Drug Estimates & Trend Analysis
4.1. Dopamine Agonist Market: Drug Segment Dashboard
4.2. Dopamine Agonist Market: By Drug Movement Analysis, 2024 & 2030 (USD Million)
4.3. Non-Ergot Dopamine Agonists
4.3.1. Non-Ergot Dopamine Agonists Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
4.4. Ergot Alkaloids
4.4.1. Ergot Alkaloids Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 5. Dopamine Agonist Market: Application Estimates & Trend Analysis
5.1. Dopamine Agonist Market: Application Segment Dashboard
5.2. Dopamine Agonist Market: By Application Movement Analysis, 2024 & 2030 (USD Million)
5.3. Parkinson's Disease
5.3.1. Parkinson's Disease Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
5.4. Restless Legs Syndrome (RLS)
5.4.1. Restless Legs Syndrome (RLS) Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
5.5. Hyperprolactinemia
5.5.1. Hyperprolactinemia Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
5.6. Others
5.6.1. Others Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 6. Dopamine Agonist Market: Route of Administration Estimates & Trend Analysis
6.1. Dopamine Agonist Market: Route of Administration Segment Dashboard
6.2. Dopamine Agonist Market: By Route of Administration Movement Analysis, 2024 & 2030 (USD Million)
6.3. Oral
6.3.1. Oral Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
6.4. Injectable
6.4.1. Injectable Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
6.5. Others
6.5.1. Others Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 7. Dopamine Agonist Market: Distribution Channel Estimates & Trend Analysis
7.1. Dopamine Agonist Market: Distribution Channel Segment Dashboard
7.2. Dopamine Agonist Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
7.3. Retail Pharmacies
7.3.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
7.4. Hospital Pharmacies
7.4.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
7.5. Other Pharmacies
7.5.1. Other Pharmacies Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 8. Dopamine Agonist Market: Regional Estimates & Trend Analysis
8.1. Dopamine Agonist Market Share, by Region, 2024 & 2030 (USD Million)
8.2. North America
8.2.1. North America Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.2.2. U.S.
8.2.2.1. Key Country Dynamics
8.2.2.2. Target Disease Prevalence
8.2.2.3. Regulatory Framework
8.2.2.4. Reimbursement Framework
8.2.2.5. U.S. Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.2.3. Canada
8.2.3.1. Key Country Dynamics
8.2.3.2. Target Disease Prevalence
8.2.3.3. Regulatory Framework
8.2.3.4. Reimbursement Framework
8.2.3.5. Canada Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.2.4. Mexico
8.2.4.1. Key Country Dynamics
8.2.4.2. Target Disease Prevalence
8.2.4.3. Regulatory Framework
8.2.4.4. Reimbursement Framework
8.2.4.5. Mexico Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.3. Europe
8.3.1. Europe Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.3.2. UK
8.3.2.1. Key Country Dynamics
8.3.2.2. Target Disease Prevalence
8.3.2.3. Regulatory Framework
8.3.2.4. Reimbursement Framework
8.3.2.5. Uk Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.3.3. Germany
8.3.3.1. Key Country Dynamics
8.3.3.2. Target Disease Prevalence
8.3.3.3. Regulatory Framework
8.3.3.4. Reimbursement Framework
8.3.3.5. Germany Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.3.4. France
8.3.4.1. Key Country Dynamics
8.3.4.2. Target Disease Prevalence
8.3.4.3. Regulatory Framework
8.3.4.4. Reimbursement Framework
8.3.4.5. France Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.3.5. Italy
8.3.5.1. Key Country Dynamics
8.3.5.2. Target Disease Prevalence
8.3.5.3. Regulatory Framework
8.3.5.4. Reimbursement Framework
8.3.5.5. Italy Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.3.6. Spain
8.3.6.1. Key Country Dynamics
8.3.6.2. Target Disease Prevalence
8.3.6.3. Regulatory Framework
8.3.6.4. Reimbursement Framework
8.3.6.5. Spain Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.3.7. Denmark
8.3.7.1. Key Country Dynamics
8.3.7.2. Target Disease Prevalence
8.3.7.3. Regulatory Framework
8.3.7.4. Reimbursement Framework
8.3.7.5. Denmark Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.3.8. Sweden
8.3.8.1. Key Country Dynamics
8.3.8.2. Target Disease Prevalence
8.3.8.3. Regulatory Framework
8.3.8.4. Reimbursement Framework
8.3.8.5. Sweden Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.3.9. Norway
8.3.9.1. Key Country Dynamics
8.3.9.2. Target Disease Prevalence
8.3.9.3. Regulatory Framework
8.3.9.4. Reimbursement Framework
8.3.9.5. Norway Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4. Asia Pacific
8.4.1. Asia Pacific Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.2. Japan
8.4.2.1. Key Country Dynamics
8.4.2.2. Target Disease Prevalence
8.4.2.3. Regulatory Framework
8.4.2.4. Reimbursement Framework
8.4.2.5. Japan Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.3. China
8.4.3.1. Key Country Dynamics
8.4.3.2. Target Disease Prevalence
8.4.3.3. Regulatory Framework
8.4.3.4. Reimbursement Framework
8.4.3.5. China Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.4. India
8.4.4.1. Key Country Dynamics
8.4.4.2. Target Disease Prevalence
8.4.4.3. Regulatory Framework
8.4.4.4. Reimbursement Framework
8.4.4.5. India Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.5. Australia
8.4.5.1. Key Country Dynamics
8.4.5.2. Target Disease Prevalence
8.4.5.3. Regulatory Framework
8.4.5.4. Reimbursement Framework
8.4.5.5. Australia Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.6. South Korea
8.4.6.1. Key Country Dynamics
8.4.6.2. Target Disease Prevalence
8.4.6.3. Regulatory Framework
8.4.6.4. Reimbursement Framework
8.4.6.5. South Korea Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.7. Thailand
8.4.7.1. Key Country Dynamics
8.4.7.2. Target Disease Prevalence
8.4.7.3. Regulatory Framework
8.4.7.4. Reimbursement Framework
8.4.7.5. Thailand Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5. Latin America
8.5.1. Latin America Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.2. Brazil
8.5.2.1. Key Country Dynamics
8.5.2.2. Target Disease Prevalence
8.5.2.3. Regulatory Framework
8.5.2.4. Reimbursement Framework
8.5.2.5. Japan Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.3. Argentina
8.5.3.1. Key Country Dynamics
8.5.3.2. Target Disease Prevalence
8.5.3.3. Regulatory Framework
8.5.3.4. Reimbursement Framework
8.5.3.5. China Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6. Middle East and Africa
8.6.1. Middle East and Africa Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.2. South Africa
8.6.2.1. Key Country Dynamics
8.6.2.2. Target Disease Prevalence
8.6.2.3. Regulatory Framework
8.6.2.4. Reimbursement Framework
8.6.2.5. South Africa Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.3. Saudi Arabia
8.6.3.1. Key Country Dynamics
8.6.3.2. Target Disease Prevalence
8.6.3.3. Regulatory Framework
8.6.3.4. Reimbursement Framework
8.6.3.5. Saudi Arabia Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.4. UAE
8.6.4.1. Key Country Dynamics
8.6.4.2. Target Disease Prevalence
8.6.4.3. Regulatory Framework
8.6.4.4. Reimbursement Framework
8.6.4.5. UAE Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.5. Kuwait
8.6.5.1. Key Country Dynamics
8.6.5.2. Target Disease Prevalence
8.6.5.3. Regulatory Framework
8.6.5.4. Reimbursement Framework
8.6.5.5. Kuwait Dopamine Agonist Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis by Key Market Participants
9.2. Company Categorization
9.3. Participant Overview
9.4. Financial Performance
9.5. Product Bench Marking
9.6. Company Market Share Analysis, 2024
9.7. Company Profiles
9.7.1. Teva Pharmaceutical Industries Ltd
9.7.1.1. Participant’s Overview
9.7.1.2. Financial Performance
9.7.1.3. Product Benchmarking
9.7.1.4. Recent Developments/ Strategic Initiatives
9.7.2. GSK plc.
9.7.2.1. Participant’s Overview
9.7.2.2. Financial Performance
9.7.2.3. Product Benchmarking
9.7.2.4. Recent Developments/ Strategic Initiatives
9.7.3. Supernus Pharmaceuticals, Inc.
9.7.3.1. Participant’s Overview
9.7.3.2. Financial Performance
9.7.3.3. Product Benchmarking
9.7.3.4. Recent Developments/ Strategic Initiatives
9.7.4. H. Lundbeck A/S
9.7.4.1. Participant’s Overview
9.7.4.2. Financial Performance
9.7.4.3. Product Benchmarking
9.7.4.4. Recent Developments/ Strategic Initiatives
9.7.5. Amneal Pharmaceuticals LLC
9.7.5.1. Participant’s Overview
9.7.5.2. Financial Performance
9.7.5.3. Product Benchmarking
9.7.5.4. Recent Developments/ Strategic Initiatives
9.7.6. UCB Pharma
9.7.6.1. Participant’s Overview
9.7.6.2. Financial Performance
9.7.6.3. Product Benchmarking
9.7.6.4. Recent Developments/ Strategic Initiatives
9.7.7. Novartis AG
9.7.7.1. Participant’s Overview
9.7.7.2. Financial Performance
9.7.7.3. Product Benchmarking
9.7.7.4. Recent Developments/ Strategic Initiatives
9.7.8. VeroScience LLC.
9.7.8.1. Participant’s Overview
9.7.8.2. Financial Performance
9.7.8.3. Product Benchmarking
9.7.8.4. Recent Developments/ Strategic Initiatives
9.7.9. Pfizer Inc.
9.7.9.1. Participant’s Overview
9.7.9.2. Financial Performance
9.7.9.3. Product Benchmarking
9.7.9.4. Recent Developments/ Strategic Initiatives
9.7.10. Boehringer Ingelheim Pharmaceuticals, Inc.
9.7.10.1. Participant’s Overview
9.7.10.2. Financial Performance
9.7.10.3. Product Benchmarking
9.7.10.4. Recent Developments/ Strategic Initiatives
Chapter 10. Conclusion
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 North America dopamine agonist market estimates and forecasts, by country, 2018-2030 (USD Million)
Table 4 North America dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 5 North America dopamine agonist market estimates and forecasts, by drug, 2018-2030 (USD Million)
Table 6 North America dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 7 North America dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 8 U.S. dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 9 U.S. dopamine agonist market estimates and forecasts, by drugs, 2018-2030 (USD Million)
Table 10 U.S. dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 11 U.S. dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 12 Canada dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 13 Canada dopamine agonist market estimates and forecasts, by drug, 2018-2030 (USD Million)
Table 14 Canada dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 15 Canada dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 16 Mexico dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 17 Mexico dopamine agonist market estimates and forecasts, by drugs, 2018-2030 (USD Million)
Table 18 Mexico dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 19 Mexico dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 20 Europe dopamine agonist market estimates and forecasts, by country, 2018-2030 (USD Million)
Table 21 Europe dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 22 Europe dopamine agonist market estimates and forecasts, by drugs, 2018-2030 (USD Million)
Table 23 Europe dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 24 Europe dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 25 UK dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 26 UK dopamine agonist market estimates and forecasts, by drug, 2018-2030 (USD Million)
Table 27 UK dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 28 UK dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 29 Germany dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 30 Germany dopamine agonist market estimates and forecasts, by drugs, 2018-2030 (USD Million)
Table 31 Germany dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 32 Germany dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 33 France dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 34 France dopamine agonist market estimates and forecasts, by drugs, 2018-2030 (USD Million)
Table 35 France dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 36 France dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 37 Spain dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 38 Spain dopamine agonist market estimates and forecasts, by drugs, 2018-2030 (USD Million)
Table 39 Spain dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 40 Spain dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 41 Italy dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 42 Italy dopamine agonist market estimates and forecasts, by drugs, 2018-2030 (USD Million)
Table 43 Italy dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 44 Italy dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 45 Denmark dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 46 Denmark dopamine agonist market estimates and forecasts, by drugs, 2018-2030 (USD Million)
Table 47 Denmark dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 48 Denmark dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 49 Sweden dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 50 Sweden dopamine agonist market estimates and forecasts, by drugs, 2018-2030 (USD Million)
Table 51 Sweden dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 52 Sweden dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 53 Norway dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 54 Norway dopamine agonist market estimates and forecasts, by drugs, 2018-2030 (USD Million)
Table 55 Norway dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 56 Norway dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 57 Asia Pacific dopamine agonist market estimates and forecasts, by country, 2018-2030 (USD Million)
Table 58 Asia Pacific dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 59 Asia Pacific dopamine agonist market estimates and forecasts, by drugs, 2018-2030 (USD Million)
Table 60 Asia Pacific dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 61 Asia Pacific dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 62 Japan dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 63 Japan dopamine agonist market estimates and forecasts, by drugs, 2018-2030 (USD Million)
Table 64 Japan dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 65 Japan dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 66 China dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 67 China dopamine agonist market estimates and forecasts, by drugs, 2018-2030 (USD Million)
Table 68 China dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 69 China dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 70 India dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 71 India dopamine agonist market estimates and forecasts, by drugs, 2018-2030 (USD Million)
Table 72 India dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 73 India dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 74 South Korea dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 75 South Korea dopamine agonist market estimates and forecasts, by drugs, 2018-2030 (USD Million)
Table 76 South Korea dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 77 South Korea dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 78 Australia dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 79 Australia dopamine agonist market estimates and forecasts, by drugs, 2018-2030 (USD Million)
Table 80 Australia dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 81 Australia dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 82 Thailand dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 83 Thailand dopamine agonist market estimates and forecasts, by drugs, 2018-2030 (USD Million)
Table 84 Thailand dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 85 Thailand dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 86 Latin America dopamine agonist market estimates and forecasts, by country, 2018-2030 (USD Million)
Table 87 Latin America dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 88 Latin America dopamine agonist market estimates and forecasts, by drugs, 2018-2030 (USD Million)
Table 89 Latin America dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 90 Latin America dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 91 Brazil dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 92 Brazil dopamine agonist market estimates and forecasts, by drug, 2018-2030 (USD Million)
Table 93 Brazil dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 94 Brazil dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 95 Argentina dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 96 Argentina dopamine agonist market estimates and forecasts, by drugs, 2018-2030 (USD Million)
Table 97 Argentina dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 98 Argentina dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 99 MEA dopamine agonist market estimates and forecasts, by country, 2018-2030 (USD Million)
Table 100 MEA dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 101 MEA dopamine agonist market estimates and forecasts, by drugs, 2018-2030 (USD Million)
Table 102 MEA dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 103 MEA dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 104 South Africa dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 105 South Africa dopamine agonist market estimates and forecasts, by drugs, 2018-2030 (USD Million)
Table 106 South Africa dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 107 South Africa dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 108 UAE dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 109 UAE dopamine agonist market estimates and forecasts, by drugs, 2018-2030 (USD Million)
Table 110 UAE dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 111 UAE dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 112 Saudi Arabia dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 113 Saudi Arabia dopamine agonist market estimates and forecasts, by drugs, 2018-2030 (USD Million)
Table 114 Saudi Arabia dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 115 Saudi Arabia dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
Table 116 Kuwait dopamine agonist market estimates and forecasts, by application, 2018-2030 (USD Million)
Table 117 Kuwait dopamine agonist market estimates and forecasts, by drugs, 2018-2030 (USD Million)
Table 118 Kuwait dopamine agonist market estimates and forecasts, by route of administration, 2018-2030 (USD Million)
Table 119 Kuwait dopamine agonist market estimates and forecasts, by distribution channel, 2018-2030 (USD Million)
List of Figures
Figure 1 Dopamine agonist market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Value chain-based sizing & forecasting
Figure 6 QFD modelling for market share assessment
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Application segment snapshot
Figure 10 Drug and application segment snapshot
Figure 11 Route of administration and distribution channel segment snapshot
Figure 12 Competitive landscape snapshot
Figure 13 Pharmaceutical market, (USD Billion)
Figure 14 Market dynamics
Figure 15 Porter’s five forces analysis
Figure 16 PESTLE analysis
Figure 17 Dopamine agonist market: Drug outlook and key takeaways
Figure 18 Dopamine agonist market: Drug movement analysis
Figure 19 Ergot alkaloids market estimates and forecast, 2018-2030 (USD Million)
Figure 20 Non-ergot dopamine agonists market estimates and forecast, 2018-2030 (USD Million)
Figure 21 Dopamine agonist market: Application outlook and key takeaways
Figure 22 Dopamine agonist market: Application movement analysis
Figure 23 Parkinson's disease market estimates and forecast, 2018-2030 (USD Million)
Figure 24 Restless Legs Syndrome (RLS) market estimates and forecast, 2018-2030 (USD Million)
Figure 25 Hyperprolactinemia market estimates and forecast, 2018-2030 (USD Million)
Figure 26 Others market estimates and forecasts, 2018-2030 (USD Million)
Figure 27 Dopamine agonist market: Route of administration outlook and key takeaways
Figure 28 Dopamine agonist market: Route of administration movement analysis
Figure 29 Oral market estimates and forecast, 2018-2030 (USD Million)
Figure 30 Injectable market estimates and forecast, 2018-2030 (USD Million)
Figure 31 Others market estimates and forecast, 2018-2030 (USD Million)
Figure 32 Dopamine agonist market: Distribution channel outlook and key takeaways
Figure 33 Dopamine agonist market: Distribution channel movement analysis
Figure 34 Retail pharmacies market estimates and Forecast, 2018-2030 (USD Million)
Figure 35 Hospital pharmacies market estimates and forecast, 2018-2030 (USD Million)
Figure 36 Other pharmacies market estimates and forecast, 2018-2030 (USD Million)
Figure 37 Dopamine agonist market revenue, by region, 2024 & 2030, (USD Million)
Figure 38 Regional marketplace: Key takeaways
Figure 39 Regional marketplace: Key takeaways
Figure 40 North America dopamine agonist market estimates and forecasts, 2018-2030 ((USD Million)
Figure 41 Key country dynamics
Figure 42 Target disease prevalence
Figure 43 U.S. dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 44 Key country dynamics
Figure 45 Target disease prevalence
Figure 46 Canada dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 47 Mexico dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 48 Key country dynamics
Figure 49 Target disease prevalence
Figure 50 Europe dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 51 Key country dynamics
Figure 52 Target disease prevalence
Figure 53 UK dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 54 Key country dynamics
Figure 55 Target disease prevalence
Figure 56 Germany dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 57 Key country dynamics
Figure 58 Target disease prevalence
Figure 59 France dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 60 Key country dynamics
Figure 61 Target disease prevalence
Figure 62 Spain dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 63 Key country dynamics
Figure 64 Target disease prevalence
Figure 65 Italy dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 66 Key country dynamics
Figure 67 Target disease prevalence
Figure 68 Denmark dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 69 Key country dynamics
Figure 70 Target disease prevalence
Figure 71 Sweden dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 72 Key country dynamics
Figure 73 Target disease prevalence
Figure 74 Norway dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 75 Rest of Europe dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 76 Asia Pacific dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 77 Key country dynamics
Figure 78 Target disease prevalence
Figure 79 Japan dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 80 Key country dynamics
Figure 81 Target disease prevalence
Figure 82 China dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 83 Key country dynamics
Figure 84 Target disease prevalence
Figure 85 India dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 86 Key country dynamics
Figure 87 Target disease prevalence
Figure 88 Australia dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 89 Key country dynamics
Figure 90 Thailand dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 91 Key country dynamics
Figure 92 South Korea dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 93 Rest of Asia Pacific dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 94 Latin America dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 95 Key country dynamics
Figure 96 Target disease prevalence
Figure 97 Brazil dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 98 Key country dynamics
Figure 99 Target disease prevalence
Figure 100 Argentina dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 101 Rest of Latin America dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 102 MEA dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 103 Key country dynamics
Figure 104 Target disease prevalence
Figure 105 South Africa dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 106 Key country dynamics
Figure 107 Target disease prevalence
Figure 108 Saudi Arabia dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 109 Key country dynamics
Figure 110 Target disease prevalence
Figure 111 UAE dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 112 Key country dynamics
Figure 113 Target disease prevalence
Figure 114 Kuwait dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)
Figure 115 Rest of MEA dopamine agonist market estimates and forecasts, 2018-2030 (USD Million)

Companies Mentioned

The major companies profiled in this Dopamine Agonist market report include:
  • Teva Pharmaceutical Industries Ltd
  • GSK plc.
  • Supernus Pharmaceuticals, Inc.
  • H. Lundbeck A/S
  • Amneal Pharmaceuticals LLC
  • UCB Pharma
  • Novartis AG
  • VeroScience LLC.
  • Pfizer Inc.
  • Boehringer Ingelheim Pharmaceuticals, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages153
PublishedFebruary 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 1.31 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.83 Billion
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Parkinson's Disease Treatment - Global Strategic Business Report - Product Image

Parkinson's Disease Treatment - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Parkinson Disease Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Parkinson Disease Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Asia-Pacific Oral Anti-Diabetic Drug - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Asia-Pacific Oral Anti-Diabetic Drug - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 70 Pages
  • Asia Pacific
From
Parkinson's Disease Drugs - Global Strategic Business Report - Product Image

Parkinson's Disease Drugs - Global Strategic Business Report

  • Report
  • 94 Pages
  • Global
From
Europe Oral Anti-Diabetic Drug - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Europe Oral Anti-Diabetic Drug - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 70 Pages
  • Europe
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.